BioSpace News Archive

Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023.

Merrimack Pharmaceuticals, Inc. announced its full year 2023 financial results for the period ended December 31, 2023.

Hyperfine, Inc., the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance brain imaging system—the Swoop® system, announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, March 21, 2024.

BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BRUKINSA® (zanubrutinib) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), in combination with the anti-CD20 monoclonal antibody obinutuzumab, after two or more lines of systemic therapy.

Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that it has opened a new 50,000-square-foot facility in Wuxi, China.

Apogee Therapeutics, Inc. announced the pricing of its upsized previously announced underwritten public offering of 6,774,193 shares of common stock at a public offering price per share of $62.00.

Extendicare Inc. reported results for the three and twelve months ended December 31, 2023.

Zylox-Tonbridge, a leading medical device company in the peripheral and neurovascular interventional market in China, announced a new strategic partnership with Avinger, a commercial-stage medical device company developing and marketing the first and only intra-vascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease.

BioArctic AB’s partner Eisai published a presentation including a simulation of potential future sales for Leqembi, the world’s first fully approved disease-modifying treatment for Alzheimer’s disease.

Persica Pharmaceuticals Ltd announces the completion of enrolment of participants into its Phase 1b Modic Trial.